Portfolio news Archives - Page 3 of 7

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…

Martyna Wroblewska21.04.2023

All Portfolio news

BaseLaunch Portfolio has raised over half a billion dollars to date!

We are delighted to announce that our portfolio has blown past half a billion dollars raised to now collectively reach over $550M! Just the last…

Martyna Wroblewska13.04.2023

All Portfolio news

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by…

Martyna Wroblewska13.04.2023

All Portfolio news

FimmCyte joins BaseLaunch Portfolio

Endometriosis is a painful and debilitating condition that affects one in every ten women. Despite being a common health issue, there are currently limited treatment…

Martyna Wroblewska30.03.2023

All Featured Portfolio news

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr…

Martyna Wroblewska30.11.2022

All Portfolio news

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Anaveon, a clinical-stage immuno-oncology company, announced updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as…

Martyna Wroblewska27.09.2022

All Portfolio news

Phialogics joins BaseLaunch Portfolio

We are excited to welcome Phialogics as our newest portfolio company! Basel, Switzerland. 20 September 2022 - Phialogics is a preclinical stage company developing cell-type-specific…

Martyna Wroblewska20.09.2022

All Featured Portfolio news

InCephalo AG Announces Appointment of Lauren E. Abrey, MD as Chief Medical Officer

InCephalo AG announces that Lauren E. Abrey, MD will join the company as Chief Medical Officer (CMO). Dr. Abrey will lead the clinical and medical…

Arianna30.06.2022

Anaveon_-startups_Switzerland-credit-Jasmin-Rei

All Portfolio news

Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.

One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419…

Arianna10.06.2022

All Portfolio news

Onena Medicines joins BaseLaunch Portfolio

We are excited to welcome Onena Medicines as our newest portfolio company! Onena Medicines is a Swiss-Spanish biotech company emerging from the Chan Zuckerberg Biohub…

Arianna11.05.2022

Portfolio news

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

BaseLaunch Portfolio has raised over half a billion dollars to date!

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

FimmCyte joins BaseLaunch Portfolio

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Phialogics joins BaseLaunch Portfolio

InCephalo AG Announces Appointment of Lauren E. Abrey, MD as Chief Medical Officer

Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.

Onena Medicines joins BaseLaunch Portfolio

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us